Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial.

Steinberg WM, Buse JB, Ghorbani MLM, Ørsted DD, Nauck MA

Diabetes care5 May 2017Cited by 66 (Europe PMC)

PMID28476871DOI10.2337/dc16-2747PepBankPUB-28476871

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes and high cardiovascular risk, liraglutide raised serum lipase by 28.0% compared with placebo.
In plain wordsIn adults with type 2 diabetes and high heart risk, liraglutide raised blood lipase levels more than placebo did.
Peptide
Liraglutide
Outcome
IncreaseSerum lipase increase
Study
n = 9,340
Comparator
Placebo
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated
Measurements
Serum lipase increase
28%
liraglutide vs placebo
Source sentences
Summary
Compared with the placebo group, liraglutide-treated patients had increases in serum lipase and amylase of 28.0% and 7.0%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 9,340 patients with type 2 diabetes were randomized to either liraglutide or placebo (median observation time 3.84 years).
Report a problemFND-2847687101
02HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes and high cardiovascular risk, liraglutide raised serum amylase by 7.0% compared with placebo.
In plain wordsIn adults with type 2 diabetes and high heart risk, liraglutide raised blood amylase levels more than placebo did.
Peptide
Liraglutide
Outcome
IncreaseSerum amylase increase
Study
n = 9,340
Comparator
Placebo
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated
Measurements
Serum amylase increase
7%
liraglutide vs placebo
Source sentences
Summary
Compared with the placebo group, liraglutide-treated patients had increases in serum lipase and amylase of 28.0% and 7.0%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 9,340 patients with type 2 diabetes were randomized to either liraglutide or placebo (median observation time 3.84 years).
Report a problemFND-2847687102
03HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes treated with liraglutide, serum lipase and amylase levels were increased at 6 months and then remained stable.
In plain wordsIn adults with type 2 diabetes, lipase and amylase levels rose by 6 months on liraglutide and then stayed stable.
Peptide
Liraglutide
Outcome
IncreaseTime course of lipase and amylase increases
Study
n = 9,340
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Levels were increased at 6 months and then remained stable.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 9,340 patients with type 2 diabetes were randomized to either liraglutide or placebo (median observation time 3.84 years).
Report a problemFND-2847687103
04HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes and high cardiovascular risk, acute pancreatitis was confirmed in 18 liraglutide patients and 23 placebo patients, numerically fewer with liraglutide.
In plain wordsIn adults with type 2 diabetes, acute pancreatitis was slightly less frequent with liraglutide (18 cases) than with placebo (23 cases).
Peptide
Liraglutide
Outcome
No significant changeAdjudicated acute pancreatitis
Study
n = 9,340
Comparator
Placebo
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated
Measurements
Acute pancreatitis cases
18 patients
liraglutide
Acute pancreatitis cases
23 patients
placebo
Source sentences
Summary
During the study, 18 (0.4% [1.1 events/1,000 patient-years of observation] [PYO]) liraglutide-treated and 23 (0.5% [1.7 events/1,000 PYO]) placebo patients had acute pancreatitis confirmed by adjudication.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 9,340 patients with type 2 diabetes were randomized to either liraglutide or placebo (median observation time 3.84 years).
Report a problemFND-2847687104
05HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes and a history of pancreatitis, liraglutide patients were not more likely than placebo patients to develop acute pancreatitis.
In plain wordsIn adults with type 2 diabetes and past pancreatitis, liraglutide did not make acute pancreatitis more likely than placebo.
Peptide
Liraglutide
Outcome
No significant changeAcute pancreatitis in patients with prior pancreatitis
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Liraglutide-treated patients with prior history of pancreatitis (n = 147) were not more likely to develop acute pancreatitis than similar patients in the placebo group (n = 120).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 9,340 patients with type 2 diabetes were randomized to either liraglutide or placebo (median observation time 3.84 years).
Report a problemFND-2847687105
06HumanRandomized controlled trialOther
In adults with type 2 diabetes treated with liraglutide, elevations of amylase and lipase did not predict future acute pancreatitis (positive predictive value below 1.0%).
In plain wordsIn adults with type 2 diabetes on liraglutide, raised amylase and lipase levels did not predict later acute pancreatitis.
Peptide
Liraglutide
Outcome
No significant changePredictive value of amylase and lipase elevations for acute pancreatitis
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Elevations of amylase and lipase levels did not predict future risk of acute pancreatitis (positive predictive value <1.0%) in patients treated with liraglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 9,340 patients with type 2 diabetes were randomized to either liraglutide or placebo (median observation time 3.84 years).
Report a problemFND-2847687106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 not yet recruiting · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 4NCT07617155

GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis

Peking Union Medical College Hospitaln = 396est. Sept 2026 to est. Dec 2028

Hypertriglyceridemia Induced Acute Pancreatitis · Recurrent Acute Pancreatitis · Pancreatitis Relapsing · Hypertriglyceridemia

Trial page ClinicalTrials.govUpdated 1 Jun 2026

CompletedPhase 3Results postedNCT01179048

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

Novo Nordisk A/Sn = 9,34131 Aug 2010 to 17 Dec 2015

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 17 Jul 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.